• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526

Recent Advances in the Study of 3-(6-Methyl-2-oxopyridin-1(2H)-yl)propanoic acid (CAS: 859296-04-1): A Comprehensive Research Brief

3-(6-Methyl-2-oxopyridin-1(2H)-yl)propanoic acid (CAS: 859296-04-1) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its unique structural features and potential therapeutic applications. This research brief synthesizes the latest findings from peer-reviewed literature and industry reports to provide a comprehensive overview of current developments surrounding this molecule.

The compound belongs to the class of pyridone derivatives, which have demonstrated diverse biological activities. Recent studies have focused on its role as a key intermediate in the synthesis of novel drug candidates, particularly in the development of kinase inhibitors and anti-inflammatory agents. Structural analysis reveals that the 6-methyl-2-oxopyridine moiety coupled with the propanoic acid side chain creates a pharmacophore capable of interacting with multiple biological targets.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the compound's utility as a building block for protein kinase inhibitors. The work demonstrated that 859296-04-1 serves as an effective scaffold for developing selective inhibitors of p38 MAP kinase, with modifications to the propanoic acid group significantly influencing binding affinity and selectivity. This finding opens new avenues for designing targeted therapies for inflammatory diseases.

Metabolic stability studies conducted by pharmaceutical research groups have revealed promising pharmacokinetic properties of derivatives based on this core structure. The compound shows moderate plasma protein binding and favorable metabolic stability in human liver microsome assays, suggesting good drug-like properties for further development. These characteristics make it particularly valuable for medicinal chemistry programs aiming to optimize lead compounds.

Recent synthetic methodology developments have significantly improved access to 3-(6-Methyl-2-oxopyridin-1(2H)-yl)propanoic acid. A 2024 publication in Organic Process Research & Development described a scalable, green chemistry approach to its production, achieving 85% yield with reduced environmental impact compared to traditional methods. This advancement addresses previous challenges in large-scale synthesis and supports broader research applications.

Emerging applications in chemical biology have expanded the compound's utility beyond traditional drug discovery. Researchers have successfully incorporated 859296-04-1 into PROTAC (proteolysis targeting chimera) molecules, leveraging its ability to bind specific protein targets while maintaining favorable physicochemical properties. This innovative use highlights the molecule's versatility in modern therapeutic modalities.

Ongoing research continues to explore the full potential of this compound, with several pharmaceutical companies including derivatives in their preclinical pipelines. The combination of synthetic accessibility, favorable drug-like properties, and demonstrated biological activity positions 3-(6-Methyl-2-oxopyridin-1(2H)-yl)propanoic acid as a valuable tool for both academic research and industrial drug development programs.

• 78823-57-1(1(2H)-Pyridinehexanoic acid, 2-oxo-)
• 937644-25-2(2-(6-hydroxypyridin-2-yl)acetic acid)
• 68634-48-0(3-(2-Oxopyridin-1(2H)-yl)propanoic acid)
• 1176063-22-1(1-(3-Aminopropyl)-6-methylpyridin-2(1H)-one hydrochloride)
• 412034-98-1(2-(1-Methyl-6-oxopyridin-2-yl)acetic acid)
• 889939-62-2(1,6-Dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid)
• 1119446-11-5(1-Ethyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid)
• 78838-03-6(1(2H)-Pyridineundecanoic acid, 2-oxo-)
• 1094475-34-9(ethyl 3-(2-oxopyridin-1(2H)-yl)propanoate)
• 878775-97-4(3-(2-Oxo-2H-pyridin-1-yl)-propionicacidhydrobromide)